BioNTech (NASDAQ:BNTX) Trading Up 4.4%

Shares of BioNTech SE (NASDAQ:BNTX) traded up 4.4% on Thursday . The company traded as high as $273.88 and last traded at $271.00. 16,905 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 2,197,576 shares. The stock had previously closed at $259.61.

BNTX has been the subject of a number of research reports. The Goldman Sachs Group assumed coverage on BioNTech in a report on Tuesday, May 18th. They set a “neutral” rating and a $173.00 target price for the company. Berenberg Bank set a $130.00 price objective on shares of BioNTech and gave the company a “buy” rating in a research note on Tuesday, April 6th. HC Wainwright reiterated a “hold” rating and issued a $194.00 price objective on shares of BioNTech in a research note on Tuesday. Bryan, Garnier & Co restated a “neutral” rating and set a $206.00 target price (up from $135.00) on shares of BioNTech in a research report on Monday, May 17th. Finally, Redburn Partners reaffirmed a “sell” rating and set a $146.00 price target on shares of BioNTech in a research report on Wednesday, June 16th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $169.83.

The firm has a 50-day moving average price of $217.35. The company has a current ratio of 2.70, a quick ratio of 2.58 and a debt-to-equity ratio of 0.09. The stock has a market cap of $66.49 billion, a price-to-earnings ratio of 45.47 and a beta of -1.58.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Sunday, May 9th. The company reported $4.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.09 by $1.30. The firm had revenue of $2.05 billion for the quarter, compared to analyst estimates of $1.40 billion. BioNTech had a return on equity of 91.61% and a net margin of 48.40%. The company’s revenue for the quarter was up 7294.9% compared to the same quarter last year. Equities research analysts forecast that BioNTech SE will post 31.59 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Baillie Gifford & Co. acquired a new position in shares of BioNTech during the 1st quarter worth about $735,723,000. Primecap Management Co. CA increased its stake in BioNTech by 4.2% during the 1st quarter. Primecap Management Co. CA now owns 4,821,718 shares of the company’s stock worth $526,483,000 after buying an additional 193,521 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of BioNTech by 31.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,074,906 shares of the company’s stock valued at $226,559,000 after acquiring an additional 500,085 shares during the last quarter. Artisan Partners Limited Partnership lifted its position in shares of BioNTech by 10.9% in the first quarter. Artisan Partners Limited Partnership now owns 1,582,256 shares of the company’s stock valued at $172,767,000 after acquiring an additional 155,682 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in shares of BioNTech by 11.1% in the first quarter. BlackRock Inc. now owns 742,858 shares of the company’s stock worth $81,112,000 after acquiring an additional 74,312 shares during the last quarter. Institutional investors and hedge funds own 12.42% of the company’s stock.

About BioNTech (NASDAQ:BNTX)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.

See Also: What is an Initial Coin Offering (ICO)?

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.